SAD Evaluation of Safety, Tolerability, PK, and PD of MDI-2517 in Healthy Participants
NCT06453824
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
48
Enrollment
INDUSTRY
Sponsor class
Conditions
Safety and Tolerability
Interventions
DRUG:
MDI-2517
OTHER:
Placebo
Sponsor
MDI Therapeutics, Inc.